Inozyme Pharma Welcomes New Director Erik Harris
Company Announcements

Inozyme Pharma Welcomes New Director Erik Harris

Inozyme Pharma ( (INZY) ) has provided an update.

Inozyme Pharma, Inc. has appointed Erik Harris, a seasoned executive with extensive experience in the biopharmaceutical industry, as a new Class II director effective October 3, 2024. With a background that includes leadership roles at Ultragenyx Pharmaceutical and Crescendo Bioscience, along with his service on the board of Denali Therapeutics, Mr. Harris brings valuable expertise to Inozyme’s Board. His compensation aligns with that of other non-employee directors and includes stock options, while an indemnification agreement protects him against certain legal expenses related to his directorship. Harris’s appointment is independent of any family ties or undisclosed transactions with the company.

For an in-depth examination of INZY stock, go to TipRanks’ Stock Analysis page.

Related Articles
Ryan AdistIs INZY a Buy, Before Earnings?
TipRanks Auto-Generated NewsdeskInozyme Pharma Reports Promising Results in SEAPORT 1 Trial
TheFlyInozyme announces ‘positive’ interim data from ongoing Phase 1 SEAPORT 1 trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App